Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study

Comment on: “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study”

“…found that the size of the humoral response was much lower than in HCs [1] . These results appear to be mostly unrelated to the use of immune-modifying therapies, in contrast to those of other research [1] . Numerous variables could have a substantial impact on the COVID-19 vaccination's efficacy.…”

“…Although the majority of IBD patients exhibited seropositivity following COVID-19 vaccinations, Macaluso et al. found that the size of the humoral response was much lower than in HCs [1] . These results appear to be mostly unrelated to the use of immune-modifying therapies, in contrast to those of other research [1] .…”

“…We would like to comment on the article, entitled “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study [1] ." Although the majority of IBD patients exhibited seropositivity following COVID-19 vaccinations, Macaluso et al.…”

COVID-19 Vaccine Booster Shot Preserves T Cells Immune Response Based on Interferon-Gamma Release Assay in Inflammatory Bowel Disease (IBD) Patients on Anti-TNFα Treatment

“…Such effects could not be found in IBD patients treated with vedolizumab or ustekinumab, which antagonize molecular mediators of inflammation distinct from the TNF pathway [ 20 , 21 ]. In the last two years, several studies have reported impaired humoral responses in IBD patients treated with infliximab or those treated with other immunosuppressants, compared to healthy controls (HCs) after one or two doses of approved COVID-19 vaccines (mainly mRNA vaccines or containing non-replicating viral vector) [ 22 , 23 , 24 , 25 ]. Furthermore, the serological response seems to decrease more rapidly in IBD patients on anti-TNFα inhibitors than those on vedolizumab [ 26 , 27 , 28 ].…”

Reply to Comment on: “Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease”

“…Conversely, a deregulation of the immune system in IBD patients could be hypothesized, including a defective spleen function [4] . Furthermore, restricting the analysis only to patients with IBD, anti-SARS-CoV-2 IgG positivity at baseline was independently associated with the median levels of IgG anti-SARS-CoV-2 after 8 weeks from the second dose of COVID-19 vaccine, together with age, treatment for IBD, and use of mRNA-1273 compared with BNT162b2 vaccine [5] . Finally, we agree with the fact that tracking underlying immunological disorders may help to identify those patients who could need additional/booster doses of vaccine, including the analysis of genetic polymorphisms [6] .…”